A Summary of the Iodine Supplementation Study Protocol (I2S2): A UK Multicentre Randomised Controlled Trial in Preterm Infants
Authors:
- Fiona WilliamsFWFiona Williams
- Robert HumeRHRobert Hume
- Simon OgstonSOSimon Ogston
- Peter BrocklehurstPBPeter Brocklehurst
- Kayleigh MorganKMKayleigh Morgan
- Edmund JuszczakEJEdmund Juszczak
- on behalf of the I2S2 teamOTon behalf of the I2S2 team
- 27 February 2014
- journal article
- research article
- Published by S. Karger AG in Neonatology
- Vol. 105 (4) , 282-289
Abstract
This paper summarises the study protocol for the randomised controlled trial of iodine supplementation in preterm infants. Iodine is essential for the synthesis of thyroxine, and thyroxine is essential for normal brain development in utero and for the first 2-3 years of life. The recommended iodine intake in parenteral nutrition regimens is 1 μg/kg/day and commercially available parenteral solutions for infants reflect these recommendations. In the absence of other iodine sources, infants are vulnerable to negative iodine balance and insufficiency. As many preterm infants are fed parenterally for prolonged periods with solutions which have been shown to be iodine-deficient, the I2S2 Trial was designed to establish whether iodine supplementation of preterm infants benefits neurodevelopment.Keywords
This publication has 2 references indexed in Scilit:
- Iodine deficiency associated with parenteral nutrition in extreme preterm infantsArchives of Disease in Childhood - Fetal and Neonatal Edition, 2003
- Guidelines for the use of vitamins, trace elements, calcium, magnesium, and phosphorus in infants and children receiving total parenteral nutrition: report of the Subcommittee on Pediatric Parenteral Nutrient Requirements from the Committee on Clinical Practice Issues of the American Society for Clinical NutritionThe American Journal of Clinical Nutrition, 1988